News articles about TESARO (NASDAQ:TSRO) have been trending somewhat positive on Tuesday, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. TESARO earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.1154214647913 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
A number of research firms have recently commented on TSRO. HC Wainwright began coverage on TESARO in a research report on Thursday, October 12th. They issued a “buy” rating and a $158.00 price objective for the company. ValuEngine cut TESARO from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Robert W. Baird reiterated a “neutral” rating and set a $125.00 price target on shares of TESARO in a research report on Monday, October 2nd. Royal Bank Of Canada started coverage on TESARO in a research report on Thursday, September 14th. They set a “sector perform” rating and a $120.00 price target for the company. Finally, Wedbush reiterated an “outperform” rating and set a $160.00 price target on shares of TESARO in a research report on Monday, September 11th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $170.19.
Shares of TESARO (TSRO) opened at 120.31 on Tuesday. TESARO has a one year low of $106.64 and a one year high of $192.94. The firm’s 50-day moving average price is $122.08 and its 200 day moving average price is $133.77. The stock’s market cap is $6.52 billion.
TESARO (NASDAQ:TSRO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.52) by ($0.30). TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The business had revenue of $29.50 million during the quarter, compared to analyst estimates of $18.61 million. During the same period last year, the company earned ($1.28) EPS. The business’s revenue for the quarter was down 17.6% on a year-over-year basis. Equities research analysts expect that TESARO will post ($8.72) EPS for the current fiscal year.
In other TESARO news, SVP Martin H. Jr. Huber sold 592 shares of TESARO stock in a transaction on Friday, September 22nd. The shares were sold at an average price of $118.60, for a total value of $70,211.20. Following the sale, the senior vice president now directly owns 6,943 shares in the company, valued at approximately $823,439.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Grant C. Bogle sold 14,167 shares of TESARO stock in a transaction on Friday, September 1st. The shares were sold at an average price of $135.00, for a total transaction of $1,912,545.00. The disclosure for this sale can be found here. Insiders sold 35,692 shares of company stock valued at $4,628,976 in the last three months. Company insiders own 34.60% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “TESARO (NASDAQ:TSRO) Getting Somewhat Positive Press Coverage, Analysis Finds” was reported by BBNS and is the property of of BBNS. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://baseballnewssource.com/markets/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-tesaro-tsro-share-price/1697564.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with our FREE daily email newsletter.